In these PDXs, when chemotherapy and HER2-targeted therapy (pertuzumab/trastuzumab) were administered together, a significant regression of tumor was observed after six weeks of treatment, compared with chemotherapy alone [61]. The gene discussed is ERBB2; the disease is neoplasm.